Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for ARO-ALK7 in Obesity. The expected timing is based on the latest available company guidance and may change.
6/2/25- Initiated Ph1/2a study. 11/25/25:- PR No update. 01/06/26:- AROALK7-1001 interim Ph1/2a data showed ~88% ALK7 mRNA knockdown and ~14% visceral fat reduction; more results expected 2026.
Verification
Confirm timing and program details against the company announcement or filing.